{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:53:14Z","timestamp":1768251194021,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004508","name":"Prince of Songkla University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jiac.2017.12.012","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T09:06:14Z","timestamp":1517907974000},"page":"358-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Does ciprofloxacin prophylaxis during chemotherapy induce intestinal microflora resistance to ceftazidime in children with cancer?"],"prefix":"10.1016","volume":"24","author":[{"given":"Wanutsanun","family":"Tunyapanit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sureerat","family":"Chelae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6428-2305","authenticated-orcid":false,"given":"Kamolwish","family":"Laoprasopwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.12.012_bib1","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/INF.0b013e3182793610","article-title":"Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy","volume":"32","author":"Laoprasopwattana","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jiac.2017.12.012_bib2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.12.012_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JCM.42.3.1089-1094.2004","article-title":"Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients","volume":"42","author":"Rodriguez-Bano","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jiac.2017.12.012_bib4","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s10096-014-2193-9","article-title":"High rates of intestinal colonisation with fluoroquinolone-resistant ESBL-harbouring Enterobacteriaceae in hospitalised patients with antibiotic-associated diarrhoea","volume":"33","author":"Vervoort","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.012_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tmaid.2017.01.003","article-title":"Fluoroquinolone antibiotic users select fluoroquinolone-resistant ESBL-producing Enterobacteriaceae (ESBL-PE) - data of a prospective traveller study","volume":"16","author":"Kantele","year":"2017","journal-title":"Trav Med Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.012_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/08880010701703636","article-title":"Clinical outcome of febrile neutropenia in children with cancer using ceftazidime and aminoglycosides","volume":"24","author":"Laoprasopwattana","year":"2007","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.jiac.2017.12.012_bib7","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/j.1469-0691.2010.03349.x","article-title":"Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M beta-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital","volume":"17","author":"Cassier","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2017.12.012_bib8","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jac\/dkr103","article-title":"Correlation between antibiotic consumption and resistance of Gram-negative bacteria causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009","volume":"66","author":"Lai","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.12.012_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000329661","article-title":"Incidence of fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States","volume":"57","author":"Bhusal","year":"2011","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2017.12.012_bib10","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.ijid.2010.12.010","article-title":"Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies","volume":"15","author":"Chong","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.012_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/cncr.24812","article-title":"Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms","volume":"116","author":"Rangaraj","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jiac.2017.12.012_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/dkm514","article-title":"Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution","volume":"61","author":"Cattaneo","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.12.012_bib13","series-title":"Manual of clinical microbiology","author":"Edwin","year":"1985"},{"key":"10.1016\/j.jiac.2017.12.012_bib14","series-title":"Manual of clinical microbiology","author":"Patrick RM","year":"1995"},{"key":"10.1016\/j.jiac.2017.12.012_bib15","series-title":"Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S19","author":"Clinical and Laboratory Standards Institute","year":"2009"},{"key":"10.1016\/j.jiac.2017.12.012_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1078155214567161","article-title":"A\u00a0single-center evaluation of the risk for colonization or bacteremia with piperacillin-tazobactam- and cefepime-resistant bacteria in patients with acute leukemia receiving fluoroquinolone prophylaxis","volume":"22","author":"Nguyen","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.jiac.2017.12.012_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s15010-012-0354-2","article-title":"Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study","volume":"41","author":"Orsi","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2017.12.012_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhin.2011.01.014","article-title":"Risk factors and clinical significance of ertapenem-resistant Klebsiella pneumoniae in hospitalised patients","volume":"78","author":"Orsi","year":"2011","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.jiac.2017.12.012_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1086\/505393","article-title":"A\u00a0randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies","volume":"43","author":"Bow","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.012_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pbc.23245","article-title":"Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia","volume":"58","author":"Karaman","year":"2012","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.jiac.2017.12.012_bib21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/pbc.22100","article-title":"Piperacillin\/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study","volume":"53","author":"Uygun","year":"2009","journal-title":"Pediatr Blood Canc"},{"key":"10.1016\/j.jiac.2017.12.012_bib22","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/cncr.22205","article-title":"Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions","volume":"107","author":"Leibovici","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jiac.2017.12.012_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/QCO.0000000000000038","article-title":"Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact","volume":"27","author":"Trecarichi","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.012_bib24","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2017.12.012_bib25","doi-asserted-by":"crossref","first-page":"e0148386","DOI":"10.1371\/journal.pone.0148386","article-title":"Agent based modeling of human gut microbiome interactions and perturbations","volume":"11","author":"Shashkova","year":"2016","journal-title":"PLos One"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17303136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17303136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:29Z","timestamp":1761159449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17303136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1341321X17303136"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.12.012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does ciprofloxacin prophylaxis during chemotherapy induce intestinal microflora resistance to ceftazidime in children with cancer?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}